Indications
Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).
Composition
- Active substance
- agalsidase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Replagal
- Active substance
- agalsidase alfa
- ATC code
- A16AB03
- Therapeutic area
- Fabry Disease
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Authorised
- EU authorisation